Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia
CAR-T and blinatumomab therapies demonstrate comparable safety and efficacy as bridging treatments to HSCT in patients with R/R B-ALL. Further studies are needed to optimize these treatment strategies.
Authors
- Yang Cao (ORCID: https://orcid.org/0000-0002-0058-614X)
- Hao Xu (ORCID: https://orcid.org/0000-0001-8966-9998)
- Wenyue Cao (ORCID: https://orcid.org/0000-0001-8718-6634)
- Ningwen Li
- Gaoxiang Wang (ORCID: https://orcid.org/0000-0001-9445-0501)
- Yicheng Zhang (ORCID: https://orcid.org/0000-0003-4300-0900)
- Yang Yang (ORCID: https://orcid.org/0000-0002-9840-3590)
- Jue Wang (ORCID: https://orcid.org/0000-0002-9948-4783)
- Na Wang (ORCID: https://orcid.org/0000-0002-4578-4609)
- Yun Li (ORCID: https://orcid.org/0000-0002-8028-9937)
- Jinhuan Xu (ORCID: https://orcid.org/0000-0002-4344-6913)
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1186/s12967-025-06399-1
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- Key Technologies Research and Development Program
- National Key Research and Development Program of China